Form 4: Axogen Director Exercises Options, Sells Shares

Axogen Director William P. Burke exercised stock options and subsequently sold a significant number of common shares under a pre-arranged trading plan.

Summary

• William P. Burke, a Director at Axogen, Inc. (AXGN), reported transactions involving the company's common stock.
• On November 5, 2025, Mr. Burke exercised 11,431 stock options at an exercise price of $8.14 per share.
• Concurrently, on November 5, 2025, he sold 11,431 shares of common stock at a weighted average price of $24.048 per share, with prices ranging from $24.00 to $24.25.
• On November 6, 2025, Mr. Burke exercised an additional 5,347 stock options at an exercise price of $8.14 per share.
• Also on November 6, 2025, he sold 5,347 shares of common stock at a weighted average price of $24.008 per share, with prices ranging from $24.00 to $24.06.
• All sales were conducted pursuant to a Rule 10b5-1(c) trading plan adopted on March 14, 2025.
• Following these transactions, Mr. Burke beneficially owns 100 shares of common stock directly and 22,818 derivative securities (stock options) directly.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions under a pre-arranged trading plan, which is generally neutral in sentiment. While insider selling can sometimes be viewed negatively, the planned nature and the profit realized by the director balance this perception.

Positives

• The director realized a substantial profit by exercising options at $8.14 and selling shares at approximately $24.00-$24.05, indicating significant stock price appreciation since the option grant.
• The transactions were executed under a Rule 10b5-1(c) trading plan, which demonstrates pre-planning and reduces concerns about opportunistic insider trading.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, potentially signaling a lack of further upside conviction from an insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing reports routine insider transactions and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if planned, might be noted by investors, but is unlikely to have a significant impact on the company's fundamentals or share price given its routine nature.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer, or a security holder.

Key Dates

Recommendation

This Form 4 reports a director's exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. Such transactions are routine and do not typically provide new fundamental information about the company's operational performance or strategic direction. While the director realized a profit, this is a personal financial event and not a direct indicator of future company performance. Therefore, based solely on this filing, a seasoned investor would likely maintain their current position, as there is no new information to warrant a change in investment thesis.

Keywords

Axogen, AXGN, Form 4, Insider Trading, Stock Options, Director, Share Sale, 10b5-1 Plan, Equity Transactions